240 related articles for article (PubMed ID: 31973227)
1. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies.
Chowdhury S; Sripathy S; Webster A; Park A; Lao U; Hsu JH; Loe T; Bedalov A; Simon JA
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973227
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
Khalil NA; Ahmed EM; Zaher AF; El-Zoghbi MS; Sobh EA
Eur J Med Chem; 2020 Feb; 187():111926. PubMed ID: 31812033
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
4. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
5. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
Peck B; Chen CY; Ho KK; Di Fruscia P; Myatt SS; Coombes RC; Fuchter MJ; Hsiao CD; Lam EW
Mol Cancer Ther; 2010 Apr; 9(4):844-55. PubMed ID: 20371709
[TBL] [Abstract][Full Text] [Related]
6. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors.
Mahajan SS; Scian M; Sripathy S; Posakony J; Lao U; Loe TK; Leko V; Thalhofer A; Schuler AD; Bedalov A; Simon JA
J Med Chem; 2014 Apr; 57(8):3283-94. PubMed ID: 24697269
[TBL] [Abstract][Full Text] [Related]
7. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
9. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile.
Rotili D; Carafa V; Tarantino D; Botta G; Nebbioso A; Altucci L; Mai A
Bioorg Med Chem; 2011 Jun; 19(12):3659-68. PubMed ID: 21306905
[TBL] [Abstract][Full Text] [Related]
10. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Hoffmann G; Breitenbücher F; Schuler M; Ehrenhofer-Murray AE
J Biol Chem; 2014 Feb; 289(8):5208-16. PubMed ID: 24379401
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
Hong JY; Fernandez I; Anmangandla A; Lu X; Bai JJ; Lin H
ACS Chem Biol; 2021 Jul; 16(7):1266-1275. PubMed ID: 34139124
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
Cui H; Kamal Z; Ai T; Xu Y; More SS; Wilson DJ; Chen L
J Med Chem; 2014 Oct; 57(20):8340-57. PubMed ID: 25275824
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.
Yoon YK; Ali MA; Wei AC; Choon TS; Osman H; Parang K; Shirazi AN
Bioorg Med Chem; 2014 Jan; 22(2):703-10. PubMed ID: 24387981
[TBL] [Abstract][Full Text] [Related]
14. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.
Seifert T; Malo M; Kokkola T; Engen K; Fridén-Saxin M; Wallén EA; Lahtela-Kakkonen M; Jarho EM; Luthman K
J Med Chem; 2014 Dec; 57(23):9870-88. PubMed ID: 25383691
[TBL] [Abstract][Full Text] [Related]
15. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
16. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
Farooqi AS; Hong JY; Cao J; Lu X; Price IR; Zhao Q; Kosciuk T; Yang M; Bai JJ; Lin H
J Med Chem; 2019 Apr; 62(8):4131-4141. PubMed ID: 30986062
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
Khanfar MA; Quinti L; Wang H; Choi SH; Kazantsev AG; Silverman RB
Eur J Med Chem; 2014 Apr; 76():414-26. PubMed ID: 24602787
[TBL] [Abstract][Full Text] [Related]
18. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
Zhang Y; Au Q; Zhang M; Barber JR; Ng SC; Zhang B
Biochem Biophys Res Commun; 2009 Sep; 386(4):729-33. PubMed ID: 19559674
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
[TBL] [Abstract][Full Text] [Related]
20. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
Disch JS; Evindar G; Chiu CH; Blum CA; Dai H; Jin L; Schuman E; Lind KE; Belyanskaya SL; Deng J; Coppo F; Aquilani L; Graybill TL; Cuozzo JW; Lavu S; Mao C; Vlasuk GP; Perni RB
J Med Chem; 2013 May; 56(9):3666-79. PubMed ID: 23570514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
